A Randomized Placebo Controlled Phase II Trial of Afatinib (BIBW2992) as Adjuvant Therapy Following Chemoradiation in Patients With Head and Neck Squamous Cell Carcinoma at High Risk of Recurrence
Phase of Trial: Phase II
Latest Information Update: 06 Apr 2016
At a glance
- Drugs Afatinib (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Orofacial cancer; Oropharyngeal cancer
- Focus Therapeutic Use
- 11 Sep 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 10 Jul 2013 Planned initiation date changed from 1 Feb 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov record.
- 10 Apr 2013 New trial record